SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

Core Insights - SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [2] - The company’s lead product candidate, GPS, targets the WT1 protein and has potential applications as both a monotherapy and in combination with other therapies for hematologic malignancies and solid tumors [2] - SELLAS is also developing SLS009, a differentiated small molecule CDK9 inhibitor, which shows promise in treating AML patients with unfavorable prognostic factors [2] Event Participation - Dr. Angelos Stergiou, President and CEO of SELLAS, will participate in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2025, at 8:20 am ET [1][2] Company Overview - SELLAS Life Sciences Group, Inc. is dedicated to the development of innovative therapeutics for a wide range of cancer types [2] - The company’s lead candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in various tumor types [2] - SLS009 is positioned as potentially the first and best-in-class CDK9 inhibitor with reduced toxicity and increased potency compared to existing options [2]